Join

Compare · CNCR vs HCXY

CNCR vs HCXY

Side-by-side comparison of Loncar Cancer Immunotherapy ETF (CNCR) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CNCR and HCXY operate in n/a (n/a), so they compete in similar markets.
  • HCXY carries a market cap of $4.43B.
  • HCXY has hit the wire 4 times in the past 4 weeks while CNCR has been quiet.
MetricCNCRHCXY
Company
Loncar Cancer Immunotherapy ETF
Hercules Capital, Inc.
Price
-
-
Market cap
-
$4.43B
1M return
-
-
1Y return
-
-
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NASDAQ
NYSE
IPO
n/a
2018
News (4w)
0
4
Recent ratings
0
0
CNCR

Loncar Cancer Immunotherapy ETF

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Latest CNCR

No recent items for Loncar Cancer Immunotherapy ETF.

Latest HCXY